<DOC>
	<DOCNO>NCT02680795</DOCNO>
	<brief_summary>This Phase 1 , open-label , nonrandomized study determine PK profile belinostat patient relapsed/refractory solid tumor hematological malignancy heterozygous homozygous UGT1A1*28 genotypes wild-type UGT1A1 gene . Enrolled patient assign 1 3 cohort ( A , B , C ) base UGT1A1 genotype</brief_summary>
	<brief_title>To Evaluate Safety Pharmacokinetics Belinostat Patients Who Have Wild-type , Heterozygous , Homozygous UGT1A1*28 Genotypes</brief_title>
	<detailed_description>This Phase 1 , open-label , nonrandomized study determine PK profile belinostat patient relapsed/refractory solid tumor hematological malignancy heterozygous homozygous UGT1A1*28 genotypes wild-type UGT1A1 gene . Enrolled patient assign 1 3 cohort ( A , B , C ) base UGT1A1 genotype Enrollment cohort occur simultaneously rather sequentially . Belinostat administer via 30-minute infusion daily Day 1 Day 5 one 21-day cycle . Clinical safety monitor patient . Blood sample PK analysis collect Day 1 Day 3 , urine sample PK analysis collect Day 1 Day 4 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>1 . Patient diagnose advanced solid tumor advance hematological malignancy relapsed/refractory , standard salvage therapy exist . 2 . Patient must receive least 1 prior systemic therapy current malignancy recover toxicity prior therapy screening . 3 . Patient adequate hematological hepatic function . 1 . Patient take UGT1A1 inhibitor ( eg , atazanavir , gemfibrozil , indinavir , ketoconazole , sorafenib ) screening . 2 . Patient HBV HCV 3 . Patient known HIV positive diagnosis . 4 . Patient congestive heart failure Class III/IV 5 . Patient previous exposure belinostat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>UGT1A1*28</keyword>
	<keyword>Belinostat</keyword>
	<keyword>beleodaq</keyword>
	<keyword>wild type genotype</keyword>
	<keyword>heterozygous genotype</keyword>
	<keyword>homozygous genotype</keyword>
</DOC>